Novartis sells off blood diagnostics division


Swiss-based company Novartis has agreed to sell off its blood transfusion diagnostics unit to Spanish blood products specialist Grifols for $1.7 billion (£1 billion). The sale will allow the company to ‘focus more sharply on [its] strategic businesses’, according to chief executive Joseph Jimenez.

Novartis acquired the blood diagnostics unit when it bought Chiron in 2006. The main point of that acquisition was to kick start their vaccine development programme. Novartis has since developed new influenza vaccines that can be produced faster than methods based on chicken eggs, for example.


Related Content

Novartis in the spotlight in mis-selling investigations

9 January 2014 Business

news image

Crackdown on pharma marketing continues with US and Japanese cases

$25bn-plus trade sharpens pharma giants’ focus

25 April 2014 Business

news image

Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process

Most Read

Flushing advice is flawed

24 August 2015 Research

news image

Protocols to restore contaminated water supplies are not based on science

Simple chemistry saving thousands of gold miners from mercury poisoning

25 August 2015 News and Analysis

news image

Basic apparatus is cutting mercury pollution and helping Indonesian miners go for gold

Most Commented

New drug treatment for alcoholism shows promise in animal studies

24 August 2015 Research

news image

Compounds that target a receptor in the brain appear less addictive with fewer negative side-effects than existing drugs

A risky business

28 August 2015 In the Pipeline

news image

Graduate research is likely the most risky time of a chemist’s career, says Derek Lowe